Ghent, 14 October 2019.
Novalis and Ghent University are proud to release OHMX.bio (www.ohmx.bio), the sixth instalment in Novalis’ portfolio of biotechnology and life sciences related companies. OHMX.bio is a Ghent based company that provides a complete R&D platform helping customers resolve their biological questions through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics.
As a spin-off initiative of Ghent University, OHMX.bio can profit from a deep academic expertise. OHMX.bio is working in the interaction field between bioinformatics and life sciences, making it a logical addition to the Novalis portfolio. Current flagships in its portfolio are ribosome profiling and third generation sequencing.
With its in-house developed high performant ribosome profiling service, OHMX.bio provides a genome-wide assessment of mRNA targeted by translating ribosomes. This highly sensitive sequencing-based technology unravels the translatome, a snapshot of RNA that is being translated. Quantification of gene-specific translation, discovery of non-canonical translation events, investigation of ribosome elongation speed and pausing, figuring out translation regulation by microRNAs and RNAbinding proteins and/or determination of mechanisms related to translation initiation and termination, are made possible.
OHMX.bio also services third generation sequencing workflows based on the Oxford Nanopore Technology. Direct DNA and RNA solutions allow for amplification-free sequencing of (ultra-)long reads and additionally allow to map their epigenetic features. Applications are everywhere, in the fields of clinical and more specifically cancer research, environmental and plant research, microbiology and microbiome analysis, genome and transcriptome research.
Novalis Biotech Incubation seeds biotechnology and life sciences related companies. Novalis develops innovative investment ideas at the early stage and supports their evolution. Our investment ideas focus on the interaction between bioinformatics and life sciences. Novalis strongly believes in applying innovative information technology to advance prevention, diagnosis, or treatment of disease.
About Ghent University
Ghent University (UGent) is a top 100 university and one of the largest Belgian universities located in the heart of Europe. We are an active partner in national and international educational, scientific and industrial cooperation. Our organization is dedicated to research and innovation with an annual research budget of >€600M and over 5500 researchers active in a wide area of life, physical and social sciences. Strong partnerships with the Ghent University Hospital (1000+ beds), VIB, IMEC and global leaders in academia and pharma/biotech industry thrive life science innovation at our university and is part of the thriving Flanders biotech region. UGent TechTransfer and the UGent Business Development Centers, such as Biomarked, support researchers in developing break-through science to bring innovations to the market.